| Cancer name | Non Small Cell Lung Cancer |
| Cancer Type | NSCLC |
| Immunotherapy type | Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy |
| Treatment | PD-L1 Ab |
| Drugstatus | Investigational |
| Drugbank ID | DB11830(DB05666) |
| Checkpoints | PD-L1 |
| Signature Type | Cell |
| Signature | Tregs |
| Official Symbol | NA |
| Mode of action | CE_D_DOWN |
| Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals. | |
| Experimental | mouse model |
| Description | 1.To investigate whether mocetinostat plus PD-L1 Ab treatment altered the relative abundance of key immune cell populations, tumor T-cell populations were measured by flow cytometry after 9 days of treatment of CT26 tumor-bearing mice. There was a statistically significant decrease in Tregs in both the mocetinostat and combination-treated cohorts compared to the vehicle plus Iso Ab-treated group. In contrast, the PD-L1 Ab-treated cohort exhibited similar levels of tumor-infiltrating Tregs compared to the vehicle plus Iso Ab-treated group. There was also a statistically significant increase in the percentage of T cells (CD3+), the percentage of CD8 + T cells and the CD8/Treg ratio in the mocetinostat and combination-treated cohorts com-pared with the vehicle plus Iso Ab-treated cohort. 2.In summary, these data demonstrate that mocetinostat and mocetinostat plus PD-L1 Ab treatment alter the T-cell repertoire similar to what has been observed in checkpoint inhibitor-responding patients . |
| PMID | 29124315 |
| Title | The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy |